New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
09:20 EDTSNY, ISISFDA PDUFA Date for Genzyme and Isis Pharmaceuticals' Kynamro
The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date for the review of Genzyme, a Sanofi company, and Isis Pharmaceuticals' Kynamro, for treatment of patients with homozygous familial hypercholesterolemia, of January 29, 2013.
News For SNY;ISIS From The Last 14 Days
Check below for free stories on SNY;ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information
06:18 EDTSNYSanofi, MyoKardia announce collaboration
Subscribe for More Information
September 16, 2014
07:33 EDTSNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use